ARTRYA®
Coronary Artery Disease.
We see you.

Northeast Georgia Health System goes live with Salix®

Successful Salix® integration commences revenue generation

PERTH, Australia, 23 July 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease, is pleased to announce that its Salix® platform has gone live within Northeast Georgia Health System (**NGHS**) with the first patient scans now processed and revenue being generated.

Highlights

- **Salix® platform is now live in clinical use in the first of NGHS' five hospitals and outpatient facilities, with the Salix® roll-out to be expanded to all other sites in the near term**
- **Salix® Coronary Anatomy platform and Salix® Coronary Plaque modules now in routine use – and will deliver both monthly subscription fees and fee-per-scan revenue on Salix® plaque assessments**
- **Artrya on track for all three U.S. foundation partners to be commercial in the near future**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:
"The team has worked incredibly hard to successfully integrate Salix® and train the clinical team at NGHS over these last few months. We are all excited to see the Georgia Heart Institute's cardiologists using Salix® on real patients across their first site and build their confidence in the product. We're already seeing strong clinical engagement that should underpin growing adoption, and we aim to have Cone Health online in the near future."

Second customer with clinical use of Salix® platform

Artrya has now successfully gone live with its second U.S. customer, with Artrya and NGHS moving through the final technical integration to full clinical deployment. The first scans have been processed through the Salix® platform with clinicians at Georgia Heart Institute, one of the largest cardiology programs in the state, serving more than 100,000 patients annually, now using Salix® output as part of routine diagnostic workflow. The team will support rollout across all five hospitals in the NGHS network in the near future.

Artrya will start generating monthly subscription revenue from use of the Salix® Coronary Anatomy, which is licensed as a SaaS platform, with the Salix® Coronary Plaque module generating fee-per-scan revenue as CCTA scans are analysed for patients presenting with suspected or confirmed coronary artery disease. The Salix® Coronary Flow module, once FDA cleared, will then be activated for clinical use and generate fee-per-scan revenues as well.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.